Haleon plc
NYSE•HLN
執行長: Mr. Brian James McNamara
板塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
上市日期: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
聯絡資訊
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
市值
$40.31B
本益比 (TTM)
29.4
26.1
股息率
2.1%
52周最高
$11.28
52周最低
$8.65
52周範圍
排名34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
基於 6 年期基本面
一般 • 4.7 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2020-2025
深度研究
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料